1 code page views remaining today. Guest accounts are limited to 2 daily page views. Register free account to get more views.
Log in Register free account

Official Description

Serum screening for cytotoxic percent reactive antibody (PRA); standard method

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86807 refers to a laboratory test specifically designed for serum screening of cytotoxic percent reactive antibody (PRA) using a standard method. This test is crucial in the context of organ transplantation, as it assesses the presence of human leukocyte antigen (HLA) antibodies in the serum of the organ recipient. The detection of these antibodies is vital because they can trigger an immune response that may lead to hyperacute rejection of the transplanted organ. Human leukocyte antigens are glycoproteins found on the surface of cell membranes, and they play a significant role in the body's immune response. There are two main classes of HLA antigens: Class I antigens, which primarily activate killer T-cells, and Class II antigens, which activate helper T-4 cells, macrophages, and B-cells. The screening process involves mixing the recipient's serum with leukocytes from a donor pool and employing various testing methods, such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), complement-dependent cytotoxicity, or anti-human globulin augmentation. The outcome of this test is expressed as a percentage of reactions observed within the sample panel; a higher percentage indicates an increased risk of organ rejection for the patient. For instances where a quicker screening method is utilized, the CPT® Code 86806 should be applied instead.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The serum screening for cytotoxic percent reactive antibody (PRA) is indicated in the following scenarios:

  • Organ Transplant Evaluation This test is performed prior to organ transplantation to assess the risk of hyperacute rejection by identifying the presence of HLA antibodies in the recipient's serum.
  • Assessment of Immune Response It helps evaluate the immune response of the recipient towards potential donor organs, which is critical for successful transplantation outcomes.

2. Procedure

The procedure for conducting the serum screening for cytotoxic PRA involves several detailed steps:

  • Step 1: Sample Collection A blood sample is drawn from the organ recipient to obtain serum, which will be used for the screening test.
  • Step 2: Preparation of Donor Leukocytes Leukocytes from a pool of donors are prepared for testing. This pool is essential to ensure a diverse representation of HLA types.
  • Step 3: Mixing Serum with Donor Leukocytes The recipient's serum is mixed with the prepared donor leukocytes. This step is crucial as it allows for the interaction between the recipient's antibodies and the donor's HLA antigens.
  • Step 4: Testing Method Application Various testing methods are employed to determine the percentage of cytotoxic reactions. These methods may include flow cytometry, enzyme-linked immunosorbent assay (ELISA), complement-dependent cytotoxicity, or anti-human globulin augmentation.
  • Step 5: Reaction Assessment The reactions are assessed, and the percentage of cytotoxicity is calculated. A higher percentage indicates a greater risk of organ rejection.

3. Post-Procedure

After the serum screening for cytotoxic PRA is completed, the results are analyzed and reported to the healthcare provider. The findings will guide the medical team in determining the compatibility of the organ donor with the recipient. If a high percentage of cytotoxicity is detected, further evaluations and considerations for alternative donor options may be necessary to minimize the risk of rejection. The recipient may also be monitored for any signs of immune response or complications related to the transplant process.

Short Descr CYTOTOXIC ANTIBODY SCREENING
Medium Descr SERUM SCREENING % REACTIVE ANTIBODY STANDRD METH
Long Descr Serum screening for cytotoxic percent reactive antibody (PRA); standard method
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 2
CCS Clinical Classification 235 - Other Laboratory
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
AY Item or service furnished to an esrd patient that is not for the treatment of esrd
Date
Action
Notes
Pre-1990 Added Code added.
Code
Description
Code
Description